GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Interest Coverage

Next Science (ASX:NXS) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Next Science's Operating Income for the six months ended in Dec. 2023 was A$-12.60 Mil. Next Science's Interest Expense for the six months ended in Dec. 2023 was A$-0.50 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Next Science's Interest Coverage or its related term are showing as below:


ASX:NXS's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.56
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Next Science Interest Coverage Historical Data

The historical data trend for Next Science's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Next Science Interest Coverage Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial - - - - -

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only - - N/A - -

Competitive Comparison of Next Science's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Next Science's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Next Science's Interest Coverage falls into.



Next Science Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Next Science's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Next Science's Interest Expense was A$-1.10 Mil. Its Operating Income was A$-25.61 Mil. And its Long-Term Debt & Capital Lease Obligation was A$1.03 Mil.

Next Science did not have earnings to cover the interest expense.

Next Science's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the six months ended in Dec. 2023, Next Science's Interest Expense was A$-0.50 Mil. Its Operating Income was A$-12.60 Mil. And its Long-Term Debt & Capital Lease Obligation was A$1.03 Mil.

Next Science did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Next Science  (ASX:NXS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Next Science Interest Coverage Related Terms

Thank you for viewing the detailed overview of Next Science's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Next Science (ASX:NXS) Business Description

Traded in Other Exchanges
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines